Ocular Therapeutix (NASDAQ:OCUL) Trading 3.3% Higher - Should You Buy?

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) shares traded up 3.3% on Tuesday . The stock traded as high as $6.08 and last traded at $6.13. 252,184 shares traded hands during trading, a decline of 84% from the average session volume of 1,553,186 shares. The stock had previously closed at $5.93.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $17.00.

Ocular Therapeutix Stock Performance

The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -5.71 and a beta of 1.34. The stock's 50-day moving average is $7.74 and its 200 day moving average is $8.86.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. As a group, analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Remove Ads

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Donald Notman sold 11,119 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,895 shares of company stock valued at $283,772. Corporate insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $28,000. Atlas Capital Advisors Inc. purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $53,000. Capital Performance Advisors LLP purchased a new position in shares of Ocular Therapeutix during the 3rd quarter worth approximately $70,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 8,446 shares in the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.